Canaccord Reiterates $70 Price Target On Ayr Wellness Following New Jersey Acquisition

On September 16, Ayr Wellness (CSE: AYR.a) closed their Garden State Dispensary acquisition, a New Jersey-based vertically integrated operator. Garden State has 1 of the 12 vertical licenses within the state. The company currently has 3 open dispensaries and a 30,000 square foot cultivation and production facility.

The total consideration for the deal came in at US$101 million, which is split up into US$41 million in cash, US$30 million in Ayr Wellness shares, and US$30 million in a promissory note. The team can earn a potential additional US$97 million if they hit revenue targets, paid in a mixture of cash, promissory notes, and shares.

Ayr Wellness currently has only 6 analysts covering the stock, with an average 12-month price target of $70, or a 135% upside. Out of the 6 analysts, 2 have strong buy ratings and the other 4 have buy ratings. The street high sits at $84 while the lowest price target is $35.

After the closing of the deal, Canaccord released a note where they reiterated their $70 12-month price target and buy rating. They say that management has estimated they paid, inclusive of earn-outs, 4x 2022 adjusted EBITDA. Because of this, they believe that adjusted EBITDA was in the range of US$50 million, putting revenue “well in excess of US$100M from this asset.”

They believe these estimates hinge on the success of the new adult-use sales rollout that is expected to happen in New Jersey, saying, “Although we believe any near-term contribution from this asset will ultimately be heavily dependent on the speed and efficiency with which state legislators allow this market to evolve.” They peg the New Jersey adult-use market at >US$2.5 billion.

Canaccord says that with this deal closing, most of the transformational M&A has hit the books, which should translate into strong quarter over quarter and year over year growth for Ayr. They have elected to keep their forward estimates the same at $375.5 million and $113.34 million for 2021 revenue and EBITDA, respectively. These figures are expected to grow to $802.3 million and $293.3 million in 2022 respectively.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Arizona Metals: The Disappointing Kay Mine Resource Estimate

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Supreme Cannabis: Stifel-GMP Raises Price Target To $0.55 Following Q2 Results

Last week, The Supreme Cannabis Company (TSX: FIRE) announced its second quarter 2021 financial results....

Wednesday, February 17, 2021, 10:48:00 AM

Aphria: Canaccord, PI Financial Reiterate Ratings And Price Targets After Q1 Financials

Yesterday, Aphria Inc (TSX: APHA) (NASDAQ: APHA) released its fiscal first quarter results. Net revenue...

Friday, October 16, 2020, 10:09:53 AM

Jushi Holdings: PI Financial Expects Many Catalysts For H2 2021

On August 25, Jushi Holdings Inc. (CSE: JUSH) reported its full Q2 results after pre-announcing...

Sunday, August 29, 2021, 03:12:00 PM

Canaccord Raises Greenlane Renewables Price Target To $2.75

Canaccord upgraded Greenlane Renewables (TSXV: GRN) from C$1.60 to C$2.75 and reiterated their speculative buy...

Friday, January 8, 2021, 11:53:00 AM

Green Thumb: Analysts Upgrade Ratings On Back Of Earnings Beat

This morning Canaccord Genuity raised their 12-month price target on Green Thumb Industries (CSE: GTII)...

Thursday, November 12, 2020, 10:50:37 AM